An innovative wireless electrochemical card sensor for field-deployable diagnostics of Hepatitis B surface antigen

A wireless-based detection utilizing an innovative electrochemical card ( e Card) sensor controlled by a smartphone was developed for targeting Hepatitis B surface antigen (HBsAg). A simple label-free electrochemical platform allows a convenient operation for point-of-care diagnosis. A disposable sc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2023-03, Vol.13 (1), p.3523-3523, Article 3523
Hauptverfasser: Teengam, Prinjaporn, Tangkijvanich, Pisit, Chuaypen, Natthaya, Chailapakul, Orawon
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A wireless-based detection utilizing an innovative electrochemical card ( e Card) sensor controlled by a smartphone was developed for targeting Hepatitis B surface antigen (HBsAg). A simple label-free electrochemical platform allows a convenient operation for point-of-care diagnosis. A disposable screen-printed carbon electrode was modified straightforwardly layer-by-layer with chitosan followed by glutaraldehyde, allowing a simple but effective, reproducible, and stable method for covalently immobilizing antibodies. The modification and immobilization processes were verified by electrochemical impedance spectroscopy and cyclic voltammetry. The smartphone-based e Card sensor was used to quantify HBsAg by measuring the change in current response of the [Fe(CN) 6 ] 3-/4- redox couple before and after the presence of HBsAg. Under the optimal conditions, the linear calibration curve for HBsAg was found to be 10–100,000 IU/mL with a detection limit of 9.55 IU/mL. The HBsAg e Card sensor was successfully applied to detect 500 chronic HBV-infected serum samples with satisfactory results, demonstrating the excellent applicability of this system. The sensitivity and specificity of this sensing platform were found to be 97.75% and 93%, respectively. As illustrated, the proposed e Card immunosensor offered a rapid, sensitive, selective, and easy-to-use platform for healthcare providers to rapidly determine the infection status of HBV patients.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-023-30340-5